Cargando…

Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy

Gas therapy has received widespread attention from the medical community as an emerging and promising therapeutic approach to cancer treatment. Among all gas molecules, nitric oxide (NO) was the first one to be applied in the biomedical field for its intriguing properties and unique anti-tumor mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yijun, Ouyang, Xumei, Peng, Yongjun, Peng, Shaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622285/
https://www.ncbi.nlm.nih.gov/pubmed/34834332
http://dx.doi.org/10.3390/pharmaceutics13111917
_version_ 1784605657396150272
author Zhao, Yijun
Ouyang, Xumei
Peng, Yongjun
Peng, Shaojun
author_facet Zhao, Yijun
Ouyang, Xumei
Peng, Yongjun
Peng, Shaojun
author_sort Zhao, Yijun
collection PubMed
description Gas therapy has received widespread attention from the medical community as an emerging and promising therapeutic approach to cancer treatment. Among all gas molecules, nitric oxide (NO) was the first one to be applied in the biomedical field for its intriguing properties and unique anti-tumor mechanisms which have become a research hotspot in recent years. Despite the great progress of NO in cancer therapy, the non-specific distribution of NO in vivo and its side effects on normal tissue at high concentrations have impaired its clinical application. Therefore, it is important to develop facile NO-based nanomedicines to achieve the on-demand release of NO in tumor tissue while avoiding the leakage of NO in normal tissue, which could enhance therapeutic efficacy and reduce side effects at the same time. In recent years, numerous studies have reported the design and development of NO-based nanomedicines which were triggered by exogenous stimulus (light, ultrasound, X-ray) or tumor endogenous signals (glutathione, weak acid, glucose). In this review, we summarized the design principles and release behaviors of NO-based nanomedicines upon various stimuli and their applications in synergistic cancer therapy. We also discuss the anti-tumor mechanisms of NO-based nanomedicines in vivo for enhanced cancer therapy. Moreover, we discuss the existing challenges and further perspectives in this field in the aim of furthering its development.
format Online
Article
Text
id pubmed-8622285
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86222852021-11-27 Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy Zhao, Yijun Ouyang, Xumei Peng, Yongjun Peng, Shaojun Pharmaceutics Review Gas therapy has received widespread attention from the medical community as an emerging and promising therapeutic approach to cancer treatment. Among all gas molecules, nitric oxide (NO) was the first one to be applied in the biomedical field for its intriguing properties and unique anti-tumor mechanisms which have become a research hotspot in recent years. Despite the great progress of NO in cancer therapy, the non-specific distribution of NO in vivo and its side effects on normal tissue at high concentrations have impaired its clinical application. Therefore, it is important to develop facile NO-based nanomedicines to achieve the on-demand release of NO in tumor tissue while avoiding the leakage of NO in normal tissue, which could enhance therapeutic efficacy and reduce side effects at the same time. In recent years, numerous studies have reported the design and development of NO-based nanomedicines which were triggered by exogenous stimulus (light, ultrasound, X-ray) or tumor endogenous signals (glutathione, weak acid, glucose). In this review, we summarized the design principles and release behaviors of NO-based nanomedicines upon various stimuli and their applications in synergistic cancer therapy. We also discuss the anti-tumor mechanisms of NO-based nanomedicines in vivo for enhanced cancer therapy. Moreover, we discuss the existing challenges and further perspectives in this field in the aim of furthering its development. MDPI 2021-11-12 /pmc/articles/PMC8622285/ /pubmed/34834332 http://dx.doi.org/10.3390/pharmaceutics13111917 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhao, Yijun
Ouyang, Xumei
Peng, Yongjun
Peng, Shaojun
Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy
title Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy
title_full Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy
title_fullStr Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy
title_full_unstemmed Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy
title_short Stimuli Responsive Nitric Oxide-Based Nanomedicine for Synergistic Therapy
title_sort stimuli responsive nitric oxide-based nanomedicine for synergistic therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622285/
https://www.ncbi.nlm.nih.gov/pubmed/34834332
http://dx.doi.org/10.3390/pharmaceutics13111917
work_keys_str_mv AT zhaoyijun stimuliresponsivenitricoxidebasednanomedicineforsynergistictherapy
AT ouyangxumei stimuliresponsivenitricoxidebasednanomedicineforsynergistictherapy
AT pengyongjun stimuliresponsivenitricoxidebasednanomedicineforsynergistictherapy
AT pengshaojun stimuliresponsivenitricoxidebasednanomedicineforsynergistictherapy